Cargando…

Tofacitinib in the treatment of primary Sjögren’s syndrome-associated interstitial lung disease: study protocol for a prospective, randomized, controlled and open-label trial

INTRODUCTION: Tofacitinib, a selective inhibitor of JAK1 and/or JAK3, is considered to alleviate the pulmonary condition of primary Sjögren’s syndrome (pSS)-associated interstitial lung disease (ILD) through its anti-inflammatory and antifibrotic effects. METHODS AND ANALYSIS: This is a single-cente...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Ronglin, Pu, Jincheng, Wang, Yanqing, Wu, Zhenzhen, Liang, Yuanyuan, Song, Jiamin, Pan, Shengnan, Han, Fang, Yang, Lufei, Xu, Xianghuai, Tang, Jianping, Wang, Xuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676577/ https://www.ncbi.nlm.nih.gov/pubmed/38007449 http://dx.doi.org/10.1186/s12890-023-02774-0

Ejemplares similares

Predicting cardiovascular risk in a Chinese primary Sjögren’s syndrome population: development and assessment of a predictive nomogram
por: Pu, Jincheng, et al.
Publicado: (2023)

Potential Mechanisms of White Peony against Primary Sjögren's Syndrome Based on Network Pharmacology and Molecular Docking
por: Zhuang, Shuqi, et al.
Publicado: (2022)

Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China
por: Gao, Ronglin, et al.
Publicado: (2022)

The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial
por: Gao, Ronglin, et al.
Publicado: (2022)

Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
por: Pu, Jincheng, et al.
Publicado: (2021)

Osteoarthritis or arthritis? Toward understanding of primary Sjögren’s syndrome patients with arthralgia
por: Gao, Ronglin, et al.
Publicado: (2023)

The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
por: Wang, Xuan, et al.
Publicado: (2021)

A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients
por: Bai, Wei, et al.
Publicado: (2023)

Mesenchymal stem cells negatively regulate CD4(+) T cell activation in patients with primary Sjögren syndrome through the miRNA-125b and miRNA-155 TCR pathway
por: Gong, Bangdong, et al.
Publicado: (2021)

Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis
por: Vacchi, Caterina, et al.
Publicado: (2021)

Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial
por: Ma, Xinlei, et al.
Publicado: (2023)

Interstitial lung disease in Primary Sjögren's syndrome
por: Lin, Wei, et al.
Publicado: (2022)

Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open
por: Biedermann, Luc, et al.
Publicado: (2022)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
por: Pope, Janet E., et al.
Publicado: (2019)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Evaluation of the Clinical Value of KL-6 and Tumor Markers in Primary Sjögren’s Syndrome Complicated with Interstitial Lung Disease
por: Wei, Fengqin, et al.
Publicado: (2023)

Lymphocytic interstitial pneumonia and pulmonary amyloidosis in Sjögren's syndrome
por: Avelino, Eurípedes Barsanulfo de Paula, et al.
Publicado: (2019)

Quantitative assessment of interstitial lung disease in Sjögren’s syndrome
por: Guisado-Vasco, Pablo, et al.
Publicado: (2019)

Tofacitinib
Publicado: (2012)

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
por: Curtis, Jeffrey R, et al.
Publicado: (2023)

Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a parallel, randomised, open-label, multicentre, prospective study
por: Hou, Xiaowen, et al.
Publicado: (2018)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
por: Nash, Peter, et al.
Publicado: (2020)

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open
por: Panaccione, Remo, et al.
Publicado: (2022)

The Role of the Akt Signaling Pathway in Sjögren’s Syndrome
por: Kapsogeorgou, Efstathia K., et al.
Publicado: (2023)

Characteristics of primary Sjögren’s syndrome related lymphocytic interstitial pneumonia
por: Dong, Xin, et al.
Publicado: (2020)

Biomarkers of interstitial lung disease associated with primary Sjögren's syndrome
por: Weng, Lin, et al.
Publicado: (2022)

A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
por: Wang, Shuhua, et al.
Publicado: (2023)

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
por: Kristensen, Lars Erik, et al.
Publicado: (2023)

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
por: Sandborn, William J., et al.
Publicado: (2021)

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
por: Ruperto, Nicolino, et al.
Publicado: (2017)

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Zhang, Qiyi, et al.
Publicado: (2021)

Can an Open-Label Placebo Be as Effective as a Deceptive Placebo? Methodological Considerations of a Study Protocol
por: Druart, Leo, et al.
Publicado: (2020)

Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study
por: Yano, Rina, et al.
Publicado: (2023)

Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol
por: He, Yuqian, et al.
Publicado: (2023)

Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial
por: Wang, Mengyan, et al.
Publicado: (2023)

DNA Methylation Studies in Saliva of Patients with Sjögren’s Syndrome
por: Karagianni, Panagiota, et al.
Publicado: (2021)

Erratum to Tofacitinib
Publicado: (2012)

Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies
por: Fleischmann, Roy, et al.
Publicado: (2017)

Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice
por: Sendo, Sho, et al.
Publicado: (2019)

Feasibility of the Internet Attachment–Based Compassion Therapy in the General Population: Protocol for an Open-Label Uncontrolled Pilot Trial
por: Campos, Daniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4es96ivf4hnehs9ur4vr7bdhh7